{
    "organizations": [],
    "uuid": "e8d681e8183d9b045669db5fe687f6bbef4184c6",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-flex-pharma-reports-positive-topli/brief-flex-pharma-reports-positive-topline-data-from-exploratory-phase-2-trial-of-flx-787-in-multiple-sclerosis-idUSASC09TKC",
    "ord_in_thread": 0,
    "title": "Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 20 AM / Updated 21 minutes ago BRIEF-Flex Pharma Reports Positive Topline Data From Exploratory Phase 2 Trial Of FLX-787 In Multiple Sclerosis Reuters Staff 1 Min Read   Flex Pharma Inc: * FLEX PHARMA REPORTS POSITIVE TOPLINE DATA FROM EXPLORATORY PHASE 2 TRIAL OF FLX-787 IN MULTIPLE SCLEROSIS * FLEX PHARMA - FLX-787 REDUCED CRAMP/SPASM FREQUENCY AND INCREASED CRAMP-FREE DAYS IN MS PATIENTS IN PRE-SPECIFIED ANALYSIS OF PARALLEL TREATMENT PHASE * FLEX PHARMA INC - FLX-787 WAS GENERALLY WELL TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS REPORTED Source text for Eikon: Further company coverage:",
    "published": "2018-03-26T19:20:00.000+03:00",
    "crawled": "2018-03-26T14:30:49.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "updated",
        "minute",
        "ago",
        "pharma",
        "report",
        "positive",
        "topline",
        "data",
        "exploratory",
        "phase",
        "trial",
        "multiple",
        "sclerosis",
        "reuters",
        "staff",
        "min",
        "read",
        "flex",
        "pharma",
        "inc",
        "flex",
        "pharma",
        "report",
        "positive",
        "topline",
        "data",
        "exploratory",
        "phase",
        "trial",
        "multiple",
        "sclerosis",
        "flex",
        "pharma",
        "reduced",
        "frequency",
        "increased",
        "day",
        "m",
        "patient",
        "analysis",
        "parallel",
        "treatment",
        "phase",
        "flex",
        "pharma",
        "inc",
        "generally",
        "well",
        "tolerated",
        "serious",
        "adverse",
        "event",
        "reported",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}